VEGFA and cancer: All 102 patients received FTD/TPI plus BEV combination therapy; 5 patients were ineligible, including 3 patients who enrolled in this study within 2 weeks of completing a previous therapy, 1 patient who had no prior history of anti-VEGF therapy, and 1 patient who had another type of active cancer.